vs
Avantor, Inc.（AVTR）与Seer, Inc.（SEER）财务数据对比。点击上方公司名可切换其他公司
Avantor, Inc.的季度营收约是Seer, Inc.的396.0倍（$1.7B vs $4.2M）。Avantor, Inc.净利率更高（3.1% vs -380.7%，领先383.9%）。Seer, Inc.同比增速更快（5.0% vs -1.4%）。Avantor, Inc.自由现金流更多（$117.2M vs $-11.1M）。过去两年Seer, Inc.的营收复合增速更高（17.1% vs -0.5%）
Avantor是一家总部位于美国宾夕法尼亚州拉德诺的生物技术、化工及制药领域企业，前身为1904年成立的J.T. Baker，2010年正式更名，2019年在纽约证券交易所挂牌上市，股票代码为AVTR，为全球生命科学、医疗健康等行业客户提供核心产品与服务。
Seer, Inc.是一家总部位于美国加利福尼亚州雷德伍德城的生物技术企业，成立于2017年，专注于开发蛋白质组学研究领域的相关技术，目前在生物科研技术开发领域开展业务。
AVTR vs SEER — 直观对比
营收规模更大
AVTR
是对方的396.0倍
$4.2M
营收增速更快
SEER
高出6.4%
-1.4%
净利率更高
AVTR
高出383.9%
-380.7%
自由现金流更多
AVTR
多$128.3M
$-11.1M
两年增速更快
SEER
近两年复合增速
-0.5%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.7B | $4.2M |
| 净利润 | $52.4M | $-16.0M |
| 毛利率 | 31.5% | 52.0% |
| 营业利润率 | 7.6% | -413.8% |
| 净利率 | 3.1% | -380.7% |
| 营收同比 | -1.4% | 5.0% |
| 净利润同比 | -89.5% | 26.4% |
| 每股收益（稀释后） | $0.08 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVTRSEER
| Q4 25 | $1.7B | $4.2M | ||
| Q3 25 | $1.6B | $4.1M | ||
| Q2 25 | $1.7B | $4.1M | ||
| Q1 25 | $1.6B | $4.2M | ||
| Q4 24 | $1.7B | $4.0M | ||
| Q3 24 | $1.7B | $4.0M | ||
| Q2 24 | $1.7B | $3.1M | ||
| Q1 24 | $1.7B | $3.1M |
净利润AVTRSEER
| Q4 25 | $52.4M | $-16.0M | ||
| Q3 25 | $-711.8M | $-18.2M | ||
| Q2 25 | $64.7M | $-19.4M | ||
| Q1 25 | $64.5M | $-19.9M | ||
| Q4 24 | $500.4M | $-21.7M | ||
| Q3 24 | $57.8M | $-21.3M | ||
| Q2 24 | $92.9M | $-22.9M | ||
| Q1 24 | $60.4M | $-20.7M |
毛利率AVTRSEER
| Q4 25 | 31.5% | 52.0% | ||
| Q3 25 | 32.4% | 51.2% | ||
| Q2 25 | 32.9% | 52.1% | ||
| Q1 25 | 33.8% | 49.0% | ||
| Q4 24 | 33.4% | 50.6% | ||
| Q3 24 | 32.9% | 48.1% | ||
| Q2 24 | 34.1% | 56.3% | ||
| Q1 24 | 34.0% | 44.4% |
营业利润率AVTRSEER
| Q4 25 | 7.6% | -413.8% | ||
| Q3 25 | -40.0% | -469.4% | ||
| Q2 25 | 7.7% | -506.8% | ||
| Q1 25 | 9.3% | -493.0% | ||
| Q4 24 | 37.8% | -587.2% | ||
| Q3 24 | 7.3% | -603.3% | ||
| Q2 24 | 10.3% | -882.0% | ||
| Q1 24 | 8.7% | -821.7% |
净利率AVTRSEER
| Q4 25 | 3.1% | -380.7% | ||
| Q3 25 | -43.8% | -442.5% | ||
| Q2 25 | 3.8% | -479.5% | ||
| Q1 25 | 4.1% | -474.4% | ||
| Q4 24 | 29.7% | -543.6% | ||
| Q3 24 | 3.4% | -529.0% | ||
| Q2 24 | 5.5% | -743.8% | ||
| Q1 24 | 3.6% | -674.5% |
每股收益（稀释后）AVTRSEER
| Q4 25 | $0.08 | — | ||
| Q3 25 | $-1.04 | — | ||
| Q2 25 | $0.09 | — | ||
| Q1 25 | $0.09 | — | ||
| Q4 24 | $0.73 | — | ||
| Q3 24 | $0.08 | $-0.35 | ||
| Q2 24 | $0.14 | $-0.35 | ||
| Q1 24 | $0.09 | $-0.32 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $365.4M | $47.3M |
| 总债务越低越好 | $3.9B | — |
| 股东权益账面价值 | $5.6B | $259.3M |
| 总资产 | $11.8B | $296.1M |
| 负债/权益比越低杠杆越低 | 0.71× | — |
8季度趋势，按日历期对齐
现金及短期投资AVTRSEER
| Q4 25 | $365.4M | $47.3M | ||
| Q3 25 | $251.9M | $45.0M | ||
| Q2 25 | $449.4M | $37.9M | ||
| Q1 25 | $315.7M | $52.4M | ||
| Q4 24 | $261.9M | $40.8M | ||
| Q3 24 | $285.3M | $37.6M | ||
| Q2 24 | $272.6M | $31.9M | ||
| Q1 24 | $234.9M | $54.4M |
总债务AVTRSEER
| Q4 25 | $3.9B | — | ||
| Q3 25 | $3.9B | — | ||
| Q2 25 | $4.2B | — | ||
| Q1 25 | $4.1B | — | ||
| Q4 24 | $4.1B | — | ||
| Q3 24 | $4.9B | — | ||
| Q2 24 | $5.1B | — | ||
| Q1 24 | $5.3B | — |
股东权益AVTRSEER
| Q4 25 | $5.6B | $259.3M | ||
| Q3 25 | $5.6B | $271.8M | ||
| Q2 25 | $6.3B | $288.3M | ||
| Q1 25 | $6.1B | $311.0M | ||
| Q4 24 | $6.0B | $327.6M | ||
| Q3 24 | $5.6B | $344.7M | ||
| Q2 24 | $5.4B | $364.7M | ||
| Q1 24 | $5.3B | $383.6M |
总资产AVTRSEER
| Q4 25 | $11.8B | $296.1M | ||
| Q3 25 | $11.7B | $308.6M | ||
| Q2 25 | $12.8B | $322.5M | ||
| Q1 25 | $12.3B | $347.3M | ||
| Q4 24 | $12.1B | $366.6M | ||
| Q3 24 | $12.8B | $383.4M | ||
| Q2 24 | $12.7B | $406.6M | ||
| Q1 24 | $12.8B | $422.0M |
负债/权益比AVTRSEER
| Q4 25 | 0.71× | — | ||
| Q3 25 | 0.69× | — | ||
| Q2 25 | 0.67× | — | ||
| Q1 25 | 0.67× | — | ||
| Q4 24 | 0.68× | — | ||
| Q3 24 | 0.89× | — | ||
| Q2 24 | 0.94× | — | ||
| Q1 24 | 1.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $152.7M | $-10.8M |
| 自由现金流经营现金流 - 资本支出 | $117.2M | $-11.1M |
| 自由现金流率自由现金流/营收 | 7.0% | -264.2% |
| 资本支出强度资本支出/营收 | 2.1% | 7.0% |
| 现金转化率经营现金流/净利润 | 2.91× | — |
| 过去12个月自由现金流最近4个季度 | $495.0M | $-46.2M |
8季度趋势，按日历期对齐
经营现金流AVTRSEER
| Q4 25 | $152.7M | $-10.8M | ||
| Q3 25 | $207.4M | $-7.6M | ||
| Q2 25 | $154.4M | $-14.7M | ||
| Q1 25 | $109.3M | $-11.4M | ||
| Q4 24 | $173.3M | $-11.5M | ||
| Q3 24 | $244.8M | $-14.1M | ||
| Q2 24 | $281.1M | $-10.1M | ||
| Q1 24 | $141.6M | $-10.5M |
自由现金流AVTRSEER
| Q4 25 | $117.2M | $-11.1M | ||
| Q3 25 | $171.7M | $-7.8M | ||
| Q2 25 | $124.8M | $-15.2M | ||
| Q1 25 | $81.3M | $-12.1M | ||
| Q4 24 | $145.8M | $-12.0M | ||
| Q3 24 | $204.0M | $-16.3M | ||
| Q2 24 | $235.3M | $-11.2M | ||
| Q1 24 | $106.9M | $-11.2M |
自由现金流率AVTRSEER
| Q4 25 | 7.0% | -264.2% | ||
| Q3 25 | 10.6% | -190.5% | ||
| Q2 25 | 7.4% | -375.9% | ||
| Q1 25 | 5.1% | -287.1% | ||
| Q4 24 | 8.6% | -299.8% | ||
| Q3 24 | 11.9% | -404.7% | ||
| Q2 24 | 13.8% | -366.0% | ||
| Q1 24 | 6.4% | -365.6% |
资本支出强度AVTRSEER
| Q4 25 | 2.1% | 7.0% | ||
| Q3 25 | 2.2% | 6.9% | ||
| Q2 25 | 1.8% | 14.0% | ||
| Q1 25 | 1.8% | 15.6% | ||
| Q4 24 | 1.6% | 13.4% | ||
| Q3 24 | 2.4% | 54.4% | ||
| Q2 24 | 2.7% | 38.2% | ||
| Q1 24 | 2.1% | 24.6% |
现金转化率AVTRSEER
| Q4 25 | 2.91× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 2.39× | — | ||
| Q1 25 | 1.69× | — | ||
| Q4 24 | 0.35× | — | ||
| Q3 24 | 4.24× | — | ||
| Q2 24 | 3.03× | — | ||
| Q1 24 | 2.34× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AVTR
| Laboratory Solutions Segment | $1.1B | 67% |
| Bioscience Production Segment | $547.5M | 33% |
SEER
暂无分部数据
